Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-09-30 Regulatory Filings
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia rapporterar start av upprepad dosering i fas I klinisk studie av CAN10
Regulatory Filings Classification · 95% confidence The document is a press release from Cantargia AB announcing the start of a new phase in a clinical trial (CAN10). It provides details on the study progress, the nature of the drug, and contact information. While it mentions a PDF attachment at the end, the document itself is a standard corporate press release regarding operational/clinical updates, which falls under the 'Regulatory Filings' (RNS) category as it is a general regulatory announcement of company news.
2024-09-30 Swedish
Cantargia presenterar nya resultat på EADV 2024 som visar potentialen av CAN10-behandling vid hudsjukdomar
Report Publication Announcement Classification · 98% confidence The document is a press release from Cantargia AB announcing the presentation of new preclinical data regarding their drug candidate CAN10 at the EADV 2024 congress. It details scientific findings, quotes the CEO, and mentions ongoing clinical trials. Crucially, the document ends with a section titled "Bifogade filer" (Attached files) which links to a PDF document titled "Cantargia presenterar nya resultat på EADV 2024 som visar potentialen av CAN10 behandling vid hudsjukdomar". Since the text itself is an announcement about presenting results and explicitly points to an attached/linked document containing the core information, it fits the definition of a Report Publication Announcement (RPA) rather than the full scientific report (which would likely be classified as IP or potentially LTR/RNS if it were a formal regulatory filing, but RPA is best for announcing the release of presentation materials). Applying the 'MENU VS MEAL' rule: This is the announcement (menu) pointing to the actual presentation/data (meal). Therefore, RPA is the most appropriate classification.
2024-09-25 Swedish
Cantargia presents new results at EADV 2024 highlighting the potential of CAN10 treatment in dermatology
Report Publication Announcement Classification · 95% confidence The document is a short press release announcing that Cantargia presented new preclinical data regarding its CAN10 treatment at the EADV 2024 congress. It summarizes key findings, quotes the CEO, and provides background on the company and the drug. Crucially, under 'Attachments', it provides a direct link to the full presentation/document (a PDF) and states, 'The poster will be uploaded on Cantargia's webpage'. Since the document itself is an announcement about the presentation of results/data, and it is relatively short (4650 characters), it fits the criteria for a Report Publication Announcement (RPA) or potentially a Regulatory Filing (RNS) if it were less specific. Given that it explicitly announces the publication/presentation of specific results/posters, RPA is the most precise fit, as it signals the release of underlying material.
2024-09-25 English
Cantargia presents positive results at ESMO Congress 2024 showing benefit of nadunolimab combination therapy in cancer after relapse on PD1-inhibitors
Regulatory Filings Classification · 95% confidence The document is a press release from Cantargia announcing positive clinical trial results presented at the ESMO Congress 2024. While it contains detailed clinical data, it is structured as a corporate press release intended to inform the public and investors about recent developments. According to the 'Menu vs Meal' rule, since this is a press release announcing findings and providing a link to the actual posters/data, it falls under the category of a general regulatory announcement or press release. Given the specific nature of the content (clinical trial results), it is best classified as a Regulatory Filing (RNS) as it does not fit into the specific categories of financial reports or investor presentations.
2024-09-14 English
Cantargia presenterar positiva resultat på ESMO Congress 2024 av nadunolimab kombinationsterapi vid cancer efter progression på PD1-inhibitorer
Earnings Release Classification · 100% confidence The document is a press release from Cantargia AB announcing positive clinical trial results presented at the ESMO Congress 2024. While it contains detailed clinical data, it is structured as a corporate press release (PRESSMEDDELANDE) and concludes with a 'Bifogade filer' (Attached files) section that provides a link to the full PDF report. According to the 'Menu vs Meal' rule, since this is a short announcement summarizing findings and directing the reader to an external report, it is classified as a Report Publication Announcement. Q2 2024
2024-09-14 Swedish
Cantargia: nya data från två kliniska studier ger starkt stöd för nadunolimab effektivitet efter progression på PD1-inhibitorer
Regulatory Filings Classification · 98% confidence The document is a press release from Cantargia announcing new clinical data for their drug nadunolimab, specifically mentioning results that will be presented at the ESMO Congress 2024. It details efficacy and survival data from two studies (CANFOUR and CIRIFOUR) involving cancer patients, particularly those who progressed on PD1 inhibitors like pembrolizumab. The text concludes with a statement: "*Denna information är sådan information som Cantargia är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning.*" (This information is such information that Cantargia is obliged to disclose under the EU Market Abuse Regulation.) This structure—a company press release disclosing material, time-sensitive information under regulatory obligation—is characteristic of a general regulatory announcement, often categorized as Regulatory Filings (RNS) when it doesn't fit a more specific financial report type (like 10-K, ER, or IR). It is not a full financial report (10-K or IR), an earnings release (ER), or a presentation (IP); it is an announcement of scientific/clinical progress. Applying the 'MENU VS MEAL' rule: Although it contains detailed data, the document itself is a news release announcing the data and linking to the presentation materials/abstracts, making it an announcement rather than the final, comprehensive report itself. Given the context of mandatory disclosure under market abuse rules for non-standard financial reporting, RNS is the most appropriate general regulatory category.
2024-09-09 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.